HomeCompareVKSC vs PFE

VKSC vs PFE: Dividend Comparison 2026

VKSC yields 19.65% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VKSC wins by $21.9K in total portfolio value
10 years
VKSC
VKSC
● Live price
19.65%
Share price
$10.18
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$71.5K
Annual income
$6,488.77
Full VKSC calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — VKSC vs PFE

📍 VKSC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVKSCPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VKSC + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VKSC pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VKSC
Annual income on $10K today (after 15% tax)
$1,670.01/yr
After 10yr DRIP, annual income (after tax)
$5,515.45/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $16,804.45/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VKSC + PFE for your $10,000?

VKSC: 50%PFE: 50%
100% PFE50/50100% VKSC
Portfolio after 10yr
$60.5K
Annual income
$16,373.75/yr
Blended yield
27.06%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

VKSC
No analyst data
Altman Z
1.0
Piotroski
3/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VKSC buys
0
PFE buys
0
No recent congressional trades found for VKSC or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVKSCPFE
Forward yield19.65%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$71.5K$49.6K
Annual income after 10y$6,488.77$26,258.71
Total dividends collected$40.3K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: VKSC vs PFE ($10,000, DRIP)

YearVKSC PortfolioVKSC Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$12,665$1,964.72$9,153$693.39+$3.5KVKSC
2$15,877$2,325.48$8,593$849.25+$7.3KVKSC
3$19,713$2,724.55$8,336$1,066.78+$11.4KVKSC
4$24,254$3,161.51$8,437$1,384.80+$15.8KVKSC
5$29,587$3,635.38$9,013$1,875.40+$20.6KVKSC
6$35,803$4,144.63$10,306$2,680.72+$25.5KVKSC
7$42,996$4,687.23$12,820$4,101.38+$30.2KVKSC
8$51,267$5,260.73$17,673$6,826.70+$33.6KVKSC
9$60,718$5,862.28$27,543$12,591.86+$33.2KVKSC
10$71,457$6,488.77$49,560$26,258.71+$21.9KVKSC

VKSC vs PFE: Complete Analysis 2026

VKSCStock

Viskase Companies, Inc., together with its subsidiaries, produces and sells nonedible cellulosic, fibrous, and plastic casings for preparing and packaging processed meat products in North America, South America, Europe, Asia, and internationally. The company offers NOJAX cellulose casings for use in the automated production of hot dogs, dry mini salamis, and cooked and coarse ground sausages; and large cellulose casings for giving cylindrical or oval shape to the processed meats that are used in bologna, mortadella, deli ham, bierwurst, and dry sausages. It also provides fibrous casings for use in a range of applications, including pepperoni, salami, luncheon meats, boneless hams, and other deli-style processed meats, as well as for processed and smoked cheeses; color transfer casings for a range of natural and synthetic shades; flavor transfer casings for taste profiles; smoke transfer casings for processed meat or cheese products; and spice transfer casings for processing facility. In addition, the company offers VISDRY casings for dried or smoked sausages; VISFLEX casings for cheese and processed meat; VISFLEX casings for a range of cheese and processed meat applications; VISMAX casings for molded, and formed processed meat and poultry applications; VISLON for meat, poultry, and cheese applications; VISMOKE casings for cooked and smoked meat products, semi-dry sausages, and spreadable dry sausages; VISCOAT casings for a range of applications, including turkey, ham, and roast beef products; and POLYJAX casings for the production of hot dog, sausage, chorizo products, and meat snack sticks. Further, it offers textile spice transfer casings for transfer of the spice to the food and MEMBRA-CEL, a dialysis membrane made from regenerated cellulose. The company was founded in 1925 and is based in Lombard, Illinois. Viskase Companies, Inc. is a subsidiary of Icahn Enterprises L.P.

Full VKSC Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this VKSC vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VKSC vs SCHDVKSC vs JEPIVKSC vs OVKSC vs KOVKSC vs MAINVKSC vs JNJVKSC vs MRKVKSC vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.